Jennifer Englund joined CVRx as Senior Vice President of Global Clinical Affairs on May 1, 2024, overseeing the development and execution of the company's clinical evidence generation strategy, including designing and optimizing a pipeline of post-market studies. Englund brings over 25 years of experience in the medical device industry, most recently serving as Senior Vice President, Scientific Affairs at Monteris Medical, where she established a strong clinical portfolio that was pivotal in achieving reimb ...

Dr. Philip B. Adamson will join as Chief Medical Officer Bonnie Handke will join as Senior Vice President of Patient Access, Reimbursement, and Healthcare Economics Jennifer E. Englund joins as Senior Vice President of Global Clinical Affairs MINNEAPOLIS, May 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced three additions to its senior leadership team. Philip B. Adamson, MD, MSc, FACC, FESC, FRCP (Ed) has been appointed as Chief Med ...

| --- | --- | --- | |----------------------------------------------------|-----------------------------------------------------------------------------------------------------|-------------------------------------------| | | | | | For the | transition period from to | | | | Commission File Number: 001-40545 | | | | CVRx, Inc. (Exact name of registrant as specified in its charter) | | | | | | | Delaware (State or other jurisdiction of | | 41-1983744 (I.R.S. Employer | | incorporation or organization) | | Ide ...

ATLANTA, May 01, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether CVRx, Inc. ("CVRx" or the "Company") (NASDAQ:CVRX) complied with federal securities laws. On April 30, 2024, CVRx announced its financial and operating results for the first quarter of 2024, noting the "lower than anticipated revenue was due primarily to the performance of our U.S. Heart Failure business, where there was some disruption within our sales organization at the time of the CEO transition, which led to decreas ...

CVRx (NASDAQ:CVRX) stock is falling hard on Wednesday after posting results from its earnings report for the first quarter of 2024.The bad news for investors in CVRX stock starts with its earnings per share of 0$1.04. That’s much worse than the -54 cents per share Wall Street was expecting. It’s also wider than the -55 cents per share from the same period of the year prior.Adding to this is CVRx’s revenue of $10.77 million. That’s another miss next to analysts’ estimate of $11.37 million for the quarter. Ho ...

CVRx, Inc. (NASDAQ:CVRX) Q1 2024 Earnings Conference Call April 30, 2024 5:00 PM ET Company Participants Mike Vallie - IR Kevin Hykes - President and CEO Jared Oasheim - CFO Conference Call Participants Lilia-Celine Lozada - JPMorgan Phillip Dantoin - Piper Sandler Margaret Kaczor - William Blair Bill Plovanic - Canaccord Frank Takkinen - Lake Street Capital Markets Chase Knickerbocker - Craig-Hallum Operator Greetings, and welcome to the CVRx Q1 2024 Earnings Call. [Operator Instructions] As a reminder, th ...

Exhibit 99.1 CVRx Reports First Quarter 2024 Financial and Operating Results MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2024. Recent Highlights "We had a solid first quarter, which was offset by some commercial exec ...

CVRx, Inc. (CVRX) recently announced the availability of additional data supporting the long-term benefits of Barostim. This includes the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. These data highlight the long-term sustained benefits of Barostim in heart failure (HF) patients with reduced ejection fraction.It should be noted that BeAT-HF is a multi-center, prospective, randomized, controlled trial that began in April 2016 to develop scient ...

MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release first quarter 2024 financial and operating results after market close on Tuesday, April 30th, 2024. The Company will host a conference call to review its results at 5:00pm ...

MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release first quarter 2024 financial and operating results after market close on Tuesday, April 30th, 2024. The Company will host a conference call to review its results at 5:00pm ...